Floatz logo

Rimiducid

Myeloproliferative Neoplasm

Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

70 Active assets in the Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
Melphalan
Center for International Blood and Marrow Transplant Research
Phase 2/3BBB
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB
Nivestim
City of Hope Medical Center
Phase 3BB
Romidepsin
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Rimiducid is also rated in:

myelodysplastic syndromeActive
CCC
Indicative · Phase 2/3
51 / 100
View asset →
inborn error of immunityActive
CCC
Indicative · Phase 1/2
50 / 100
View asset →
large B-cell lymphomaActive
CCC
Indicative · Phase 2
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →